

QIBA PET Myocardial Blood Flow (MBF) Biomarker Committee (BC)

Monday, January 23, 2023, at 9 am CT

Call Summary

In attendance

Jonathan B. Moody, PhD (Co-Chair)
Martin Lodge, PhD
Nancy Obuchowski, PhD

RSNA Staff

Julie Lisiecki

Moderator: Dr. Moody

The following topics were discussed:

- Options for metanalysis publication
- Profile work
- New participants

Metanalysis publication

- A metanalysis manuscript is almost complete; some work needed on the introduction and discussion
- Potential journals for publication to consider include:
 - [Journal of Nuclear Cardiology \(JNC\)](#)
 - [Circulation: Cardiovascular Imaging](#)
 - [Journal of the American College of Cardiology \(JACC\): Cardiovascular Imaging](#)
- Appropriate repeatability metrics and significant predictors of wCV are being considered for 1300 data points and different measurands
- Dr. Obuchowski has drafted the methods and results
- Dr. Moody to draft an introduction and outline for the discussion

Profile

- Work on the claims continues
 - MFR ratio of two absolute quantities
 - Need to minimize variability
 - Focus claims on reserve
 - Plan to borrow from FDG Profile for some requirements, e.g., site, staff requirements, with possible reference/citation of the FDG-PET/CT Profile
- Help needed in drafting section 3, activities and Actors
- Additional viewpoints would be useful for this discussion

New BC participants

- Plans to expand BC participation to get additional expertise and input
- Drs. deKemp and Moody to contact the following and, if interested, they will be invited to the next BC call:
 - Ian Armstrong
 - Hans Harms
 - Chuck Hayden
 - John Prior
- Other colleagues to be invited later:
 - Sergey Nesterov
 - Jonathan Votaw
 - Jonathon Nye
 - Mark Hyun, an experienced technologist

New action items:

- Julie to invite a few new participants to the 2/13 call as identified by Drs. Moody and deKemp

Ongoing action items: (please strike if complete)

- [Dr. Moody](#) to start drafting the Nuclear Cardiologist (Actor) checklist per the [streamlined Profile template](#)
- [Dr. Moody](#) to work on protocol design tables and share papers to shared drive
- [Dr. deKemp](#) to craft a bias table and review the linearity plot, looking at K^1 vs. flow values
- [Dr. Moody](#) to work on a DRO model; will look at QIBA work with DCE-MRI
- Review needed for 3.3 Product Validation, 3.4 Periodic QA, and 3.7 Pharmaceutical Administration
- Dynamic phantom scan protocol in Section 4 Assessment Procedures to be fine-tuned by [Dr. Moody](#)

Next Call: [February 13, 2023](#), at 9 am CT (2nd and 4th Mondays) at 9 am CT

Parties interested in joining the [QIBA LinkedIn](#) page for QIBA updates should visit: <https://www.linkedin.com/company/rsna-qiba>

QIBA Process Committee Resources

- **Process Committee Leaders:** [Kevin O'Donnell, MASc](#) (Chair) | [Michael Boss, PhD](#) (Co-Chair)
- **Wiki Resources:** [Dashboard](#) | [Profiles](#) | [QIBA Profile template](#) | [How to Write a QIBA Profile](#) | [Claim Guidance](#) | [Vetting requirements](#)
- **Inventory of QIBA tools:** [QIBA LinkedIn page](#) (please join / follow) | [QIBA News](#) | [QIBA Community](#)
- **Other:** [QIBA Webpage](#) | [QIBA Wiki](#) | [QIBA Biomarker Committees](#) | [QIBA Organization Chart](#) | [Dropbox](#)
- **EndNote:** To obtain access to the RSNA EndNote citations, please email: sstanfa@rsna.org.